We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Consenting but hard-to-get

1 September 2010 By Pierre Briancon

The CEO of the U.S. biotech company says he’d be willing to sell to Sanofi, if the French pharma group raises its $69ashare offer before talks start in earnest. That’s sensible, but there’s still risk that Sanofi turns away once it takes a closer look at its target’s problems.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)